Teplizumab Drug Asset Due Diligence Report 2026

This Teplizumab Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Teplizumab can convert its Monoclonal antibody profile and CD3 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Teplizumab (query alias: teplizumab)
Modality / target	Monoclonal antibody; CD3; CD3 inhibitors
Highest global status	Approved
Originator	MacroGenics, Inc.
Active developers	Sanofi Winthrop Industrie SA, Sanofi, Sanofi-Aventis Canada, Inc.

The MCP disease footprint includes Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
ChiCTR2600122711	Phase 3	Recruiting	482	Change in glycated hemoglobin (HbA1c) from baseline to week 52
NCT07610213	Phase 1	Not yet recruiting	60	Change in Stimulated C-peptide AUC
NCT07360080	Not Applicable	Recruiting	1000	Time from teplizumab infusion start to the onset of Stage 3 T1D

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

1647-P: Insulin Initiation during Teplizumab Infusions and Partial Remission after Stage 3 Progression in a Real-World Cohort

Not Applicable; n=41; evaluation: Positive. Reported fields: Total Daily Insulin Dose = 0.19 units/kg/day ( 0 - 0.52)

Th127. Efficacy of Teplizumab in Delaying Onset of Stage 3 Type 1 Diabetes

Not Applicable; n=15; evaluation: Positive. Reported fields: Adverse Event: EBV reactivation = two adult patients developed EBV reactivation

Safety and pharmacokinetics of teplizumab in children less than 8 years of age with stage 2 type 1 diabetes

Phase 2; n=23; evaluation: Positive. Reported fields: TEAE(discontinuation) = 13.0 %

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Teplizumab addresses Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Monoclonal antibody—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 4 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2023-03-08	DRI Healthcare Trust Announces Acquisition of a Royalty Interest in the Worldwide Sales of TZIELD™ (teplizumab-mzwv) and Updates Long-Term Cash Receipts Outlook	Approved	US$100.0M upfront; US$100.0M milestones; US$200.0M stated total
2022-10-06	Sanofi completes acquisition of Provention Bio, Inc.	Approved	US$20.0M upfront; US$2,160.8M stated total
2018-05-07	Provention to develop and commercialize MacroGenics' MGD-010 for SLE worldwide	Approved	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Use of Anti-CD3 antibody for selectively depleting activated t cells”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Class crowding and differentiation versus other PD-(L)1/VEGF agents
Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
Biomarker strategy, indication selection, and head-to-head endpoint execution

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO